From: Down-regulated FST expression is involved in the poor prognosis of triple-negative breast cancer
Characteristics | No. of cases | HR of OS (95% CI) | p-value | Adjusted | Adjusted |
---|---|---|---|---|---|
HR of OSa (95% CI) | p-value | ||||
Pathological stage# | |||||
I/II | 689 | 0.45 (0.22–0.93) | 0.031* | 0.32 (0.15–0.70) | 0.004* |
III/IV | 236 | 0.37 (0.14–0.97) | 0.043* | 0.49 (0.17–1.46) | 0.203 |
Lymph node# | |||||
Negative | 427 | 0.37 (0.15–0.89) | 0.026* | 0.23 (0.09–0.62) | 0.003* |
Positive | 490 | 0.35 (0.15–0.84) | 0.018* | 0.46 (0.18–1.19) | 0.109 |
Distant metastasis# | |||||
Negative | 771 | 0.41 (0.22–0.75) | 0.004* | 0.35 (0.18–0.68) | 0.002* |
Positive | 18 | 0.67 (0.08–5.63) | 0.713 | 0.83 (0.10–7.20) | 0.867 |
PR status# | |||||
Negative | 161 | NA | 0.809 | NA | 0.996 |
Positive | 772 | 0.49 (0.28–0.86) | 0.013* | 0.42 (0.23–0.78) | 0.006* |
Molecular subtype | |||||
HR positive | 808 | 0.46 (0.25–0.85) | 0.012* | 0.39 (0.21–0.75) | 0.005* |
HER–2 positive | 36 | 0.19 (0.03–1.42) | 0.105 | 0.26 (0.04–1.97) | 0.194 |
TNBC | 91 | 3.85 (0.83–17.93) | 0.086 | 6.39 (0.78–52.34) | 0.084 |
Histological subtype# | |||||
Infiltrating ductal BC | 655 | 0.40 (0.21–0.78) | 0.007* | 0.43 (0.21–0.90) | 0.025* |
Infiltrating lobular BC | 192 | 0.29 (0.04–1.89) | 0.194 | 0.08 (0.01–0.57) | 0.012* |
Mixed BC | 24 | NA | NA | NA | NA |
Medullary BC | 3 | NA | NA | NA | NA |
Metaplastic BC | 5 | NA | NA | NA | NA |
Mucinous BC | 16 | NA | NA | NA | NA |
Others | 39 | 0.72 (0.13–3.98) | 0.703 | 0.77 (0.14–4.33) | 0.770 |